NCT04225078View on ClinicalTrials.gov

A Study to Evaluate the Effects of Loperamide (JNJ-289679) on Electrocardiogram Intervals in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 17, 2020

Primary Completion Date

December 21, 2021

Study Completion Date

January 12, 2022

Conditions
Healthy Participants
Interventions
DRUG

Loperamide

Loperamide will be administered as a single oral dose at the expected therapeutic or supratherapeutic doses respectively.

OTHER

Placebo

Matching loperamide placebo capsules will be administered orally.

DRUG

Moxifloxacin

Moxifloxacin tablets will be administered orally.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04225078 - A Study to Evaluate the Effects of Loperamide (JNJ-289679) on Electrocardiogram Intervals in Healthy Adult Participants | Biotech Hunter | Biotech Hunter